close
News Release

For Immediate Release

Live, Nationwide Community of Practice Forum to Address Strategies for Optimizing Non-Small Cell Lung Cancer Patient Care

Thursday, April 22, 2010
7:00 to 7:30 PM ET
Faculty:
Fred R. Hirsch, MD, PhD
Robert M. Jotte, MD, PhD
Cost:
Complimentary


BALTIMORE, MD—April 2, 2010—Oncologists can now register to join a complimentary, consultative Community of Practice forum to review strategies for optimizing non-small cell lung cancer (NSCLC) patient care.

On Thursday, April 22, 2010 at 7:00 PM ET, clinicians can talk with leading experts Fred R. Hirsch, MD, PhD, and Robert M. Jotte, MD, PhD, in a live, interactive audioconference and, together with fellow specialists, review methods for effectively overcoming practice barriers in key benchmark areas of NSCLC care.

Faculty

Fred R. Hirsch, MD, PhD
Professor of Medicine & Pathology
University of Colorado Cancer Center
Aurora, CO

Robert M. Jotte, MD, PhD
Developmental Co-Chair
US Oncology Lung Committee
Rocky Mountain Cancer Centers
Denver, CO

Guidelines and strategies for NSCLC detection, management, and treatment are continually evolving. Beginning in 2010, many clinicians are now expected to employ the recently published 7th edition International Association for the Study of Lung Cancer (IASLC) staging criteria, which include several changes from the previous version to provide more accurate classification of NSCLC tumors and more comprehensive information on patient prognosis.

“When it comes to determining optimal treatment strategies for patients with NSCLC, accurate staging and histology are vital; we’ve also recently learned that EGFR mutation status matters” said Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center. “I look forward to discussing the latest advances in lung cancer staging systems and reviewing additional clinical evidence and tools that we can use to improve both our practice performance and patient outcomes.”

Audioconference participants can ask questions regarding the care of NSCLC patients in advance or live on the telephone with Drs. Hirsch and Jotte. Clinicians interested in joining this complimentary Community of Practice audioconference can complete a brief online form, e-mail info@med-iq.com, or call (toll-free) 866 858 7434 to register and submit questions in advance.

This Community of Practice audioconference is part of the complimentary, American Medical Association (AMA)-standardized, certified, 3-stage performance improvement (PI) CME series, Performance Improvement Strategies in Non-Small Cell Lung Cancer. PI CME has been recognized as an important component of a physician's continuing professional development and may answer multiple credentialing and reporting needs. Clinicians can use data from Med-IQ's PI CME series to complete ABIM's Self-Directed PIM and earn credit for ABIM Maintenance of Certification.

“Performance Improvement Strategies in NSCLC is designed to help oncologists evaluate their clinical processes according to national standards of care and recent trial data regarding the management of NSCLC,” said Robert M. Jotte, MD, PhD, Developmental Co-Chair of the US Oncology Lung Committee and faculty expert for Performance Improvement Strategies in NSCLC. “The goal of this initiative is to provide clinicians with the tools needed to apply practical evidence-based strategies to their practices to improve knowledge, competency, and performance, as well as optimize patient outcomes.”

This series is sponsored by Med-IQ, an ACCME-accredited provider of CME, provided in collaboration with Oncology Today™, the CME subsidiary of US Oncology, and supported by an educational grant from Lilly USA, LLC.

To learn more about the educational resources available in this educational series, visit www.pi-iq.com/lungcancer.

About Med-IQ

Med-IQ, America's most respected continuing medical education (CME) company, is an accredited provider of CME that educates and inspires healthcare professionals through programs that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively. We are a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives. To learn more about us, visit www.Med-IQ.com.

For more information, contact:

Catherine B. Mullaney, MHA
Vice President, Audience Development
and Educational Outcomes
Med-IQ
443 543 5154
info@med-iq.com

 

Provided in collaboration with:
Oncology Today

Med-IQ: Inspiring Medical Education